Skip to main content

Table 1 Patient and disease characteristics of the entire cohort (n = 193)

From: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom

Variable Results
Male/female 83/110
Age at diagnosis, median (IQR) 32 (21–44)
Age at initiation TG, median (IQR) 43 (33–56)
Hospital
 ▪ St. Thomas’ Hospital 87 (45%)
 ▪ East Surrey Hospital 67 (35%)
 ▪ Queen Elizabeth Hospital 39 (20%)
Crohn’s disease (Montreal classification) 123 (64%)
Age at diagnosis
 ▪ <  17 (A1) 16 (19%)
 ▪ 17–40 (A2) 71 (58%)
 ▪ > 40 (A3) 29 (24%)
Location
 ▪ Ileal (L1) 38 (31%)
 ▪ Colonic (L2) 15 (15%)
 ▪ Ileocolonic (L3) 62 (50%)
 ▪ Upper gastrointestinal disease (L4) 4 (3%)
Behaviour
 ▪ Nonstricturing, nonpenetrating (B1) 45 (40%)
 ▪ Stricturing (B2) 36 (33%)
 ▪ Penetrating (B3) 26 (27%)
 ▪ Perianal disease (p) 23 (12%)
Ulcerative colitis (Montreal classification) 64 (33%)
Extent
 ▪ Proctitis (E1) 18 (30%)
 ▪ Left-sided (E2) 24 (37%)
 ▪ Pancolitis (E3) 21 (33%)
Severity
 ▪ Asymptomatic (S0) 9 (14%)
 ▪ Mild (S1) 15 (24%)
 ▪ Moderate (S2) 18 (28%)
 ▪ Severe (S3) 22 (34%)
IBD unclassified 6 (3%)
Drug failure prior to thioguanine initiation 193 (100%)
 ▪ Azathioprine 123 (58%)
 ▪ Mercaptopurine 11 (5%)
 ▪ Azathioprine and mercaptopurine 59 (27%)
 ▪ Azathiopurine and allopurinol 76 (39%)
 ▪ Anti-tumour necrosis factor 77 (40%)
 ▪ Methotrexate 36 (19%)
 ▪ Tacrolimus 8 (4%)
Gastrointestinal surgery prior to thioguanine initiation 63 (33%)
Follow-up in months, median (IQR) 36 (22–53)
Treatment duration of thioguanine (months, IQR) 23 (10–47)